Pulmonary inflammatory myofibroblastic tumor in children

Maria Wawszczak; Grażyna Kraj; Joanna Lange; Renata Langfort

doi:10.5114/polp.2023.133535

eISSN: 2300-8660
ISSN: 0031-3939

Pediatria Polska - Polish Journal of Paediatrics

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2023
vol. 98

Send email

Copy url:

abstract:

Review paper

Pulmonary inflammatory myofibroblastic tumor in children

Maria Wawszczak

¹

,

Grażyna Kraj

²

,

Joanna Lange

¹

,

Renata Langfort

³

Department of Paediatric Pneumonology and Allergology, Medical University of Warsaw, Warsaw, Poland
Department of Pediatric, Mazovian Centre for the Treatment of Lung Diseases and Tuberculosis in Otwock, Otwock, Poland
Department of Pathology, National Tuberculosis and Lung Diseases, Research Institute, Warsaw, Poland

Pediatr Pol 2023; 98 (4): 320-325

DOI: https://doi.org/10.5114/polp.2023.133535

Online publish date: 2023/12/15

View full text Get citation

PlumX metrics:

Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm characterized by mesenchymal spindle cell proliferation with a marked inflammatory infiltrate component. Although the exact etiopathology of pulmonary IMT is still not clear, gene fusions involving anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), neurotrophic tyrosine receptor kinase (NTRK), platelet-derived growth factor receptor (PDGFR) and rearranged during transfection (RET) have been recently detected in immunohistochemical assessment of this lesion. Due to its nonspecific clinical or radiological presentation, the diagnosis of IMT primarily depends on histopathological findings. Surgery remains the mainstay of treatment and provides the best chance to limit recurrence. In unresectable lesions or multifocal/metastatic disease, treatment with chemotherapy or ALK, ROS1, RET and NTRK inhibitors is recommended. The prognosis in children with IMT is generally perceived as favorable, although local invasion and metastasis have been reported.

keywords:

Pulmonary inflammatory myofibroblastic tumor in children

Maria Wawszczak 1 , Grażyna Kraj 2 , Joanna Lange 1 , Renata Langfort 3

inflammatory pseudotumor, plasma cell granuloma, inflammatory myofibroblastic tumor

Maria Wawszczak

¹

,

Grażyna Kraj

²

,

Joanna Lange

¹

,

Renata Langfort

³